NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

β地中海型貧血 - 流行病學預測 2028年

Beta-thalassemia - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 915400
出版日期 按訂單生產 內容資訊 英文 60 Pages
商品交期: 2-10個工作天內
價格
β地中海型貧血 - 流行病學預測 2028年 Beta-thalassemia - Epidemiology Forecast to 2028
出版日期: 按訂單生產內容資訊: 英文 60 Pages
簡介

新興10個國家(土耳其、俄羅斯、哥倫比亞、巴西、阿根廷、墨西哥、沙烏地阿拉伯、阿拉伯聯合大公國、中國、台灣)的2017年的β地中海型貧血的患病數估算為6萬4,655人。

本報告提供新興10個國家(土耳其、俄羅斯、哥倫比亞、巴西、阿根廷、墨西哥、沙烏地阿拉伯、阿拉伯聯合大公國、中國、台灣)的β地中海型貧血市場調查,疾病概要,流行病學的預測,各國的患病數的變化與預測,未滿足需求等資料彙整。

目錄

第1章 重要洞察

第2章 市場概要:β地中海型貧血

  • 市場佔有率和分佈(實在數值)
  • 市場佔有率與分佈(預測值)

第3章 疾病背景和概要

  • 簡介
  • 類型
  • 分子遺傳學
  • 原因和危險因素
  • 關聯的併發症
  • 病因
  • 症狀
  • 病理生理學
  • 臨床症狀
  • 診斷

第4章 流行病學和患者人口

  • 主要調查結果
  • 新興10個國家的β地中海型貧血的診斷患病數

第5章 β地中海型貧血的流行病學:各國

  • 假設和根據
  • 中國
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 台灣
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 沙烏地阿拉伯
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 阿拉伯聯合大公國
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 土耳其
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 俄羅斯
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 哥倫比亞
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 巴西
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 阿根廷
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症
  • 墨西哥
    • 總患病數
    • 診斷患病數
    • 診斷患病數:各病型
    • 併發症

第6章 β地中海型貧血的治療和管理

  • 輸血療法
  • 鐵螫合物療法
  • 鐵過剩症的治療
  • 骨髓及臍帶血移植
  • 胎兒血紅素誘導
  • 基因治療

第7章 未滿足需求

第8章 附錄

  • 調查方法

第9章 DelveInsight的服務內容

第10章 免責聲明

第11章 關於DelveInsight

目錄
Product Code: DIEI0390

DelveInsight's 'Beta-thalassemia (B-thal) - Epidemiology Forecast to 2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Beta-thalassemia in the 10 emerging markets; Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan and China.

Geography Covered

  • Turkey, Russia, China and Taiwan
  • Latin-America(Colombia, Brazil, Argentina, Mexico)
  • Middle-east (Saudi Arabia, UAE)

Study Period: 2017-2028

Beta-thalassemia Disease Understanding

Thalassemia is genetic in nature, i.e., it is passed down from parents to children. The term thalassemia is derived from the Greek, thalassa (sea) and haima (blood). It is a blood-related disorder and occurs when body cannot make enough of the protein called hemogloblin (present in red blood cells; RBCs). Due to lack of hemoglobin in RBCs, they cannot function properly and last for shorter periods. Due to the lack of healthy RBCs in the bloodstream, oxygen supply to other cells is compromised which causes tiredness, weakness, and shortness of breath among patients. This condition is called Anemia. Beta-thalassemia (B-thal) or low beta-globin occur due to mutations in the HBB gene on chromosome 11. It is inherited in an autosomal, recessive fashion. The severity of the disease depends on the nature of the mutation and on the presence of mutations in one or both alleles.

Beta-thalassemia Epidemiology

The Beta-thalassemia (B-thal) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 10 emerging market (EM) countries. The epidemiology data for Beta-thalassemia are studied through all possible division to give a better understanding about the Disease scenario in 10EM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Beta-thalassemia Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases of B-thal, total diagnosed prevalence, diagnosed prevalence by disease type and complications associated with B-thal) scenario of Beta-thalassemia (B-thal) in the 10EM covering Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan and China from 2017-2028.

The DelveInsight report also provides the epidemiology trends observed in the 10EM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Beta-thalassemia (B-thal) in 10EM was found to be 64,655, in the year 2017.

Report Scope

  • The report covers detailed overview of Beta-thalassemia explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Beta-thalassemia in 10 emerging markets covering the Turkey, Russia, Colombia, Brazil, Argentina, Mexico, Saudi Arabia, UAE, Taiwan and China.
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 10EM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by total prevalent cases of B-thal, total diagnosed prevalent cases, diagnosed prevalence by disease type and complications associated with Beta-thalassemia in 10EM.

Key strengths

  • 10 Year Forecast of Beta-thalassemia epidemiology
  • 10EM Coverage
  • Total Prevalent Cases of B-thal
  • Cases according to segmentation: total prevalent cases of B-thal, total diagnosed prevalence, diagnosed prevalence by disease type and complications associated with B-thal.
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1 Key Insights

2 B-thalassemia Market Overview at a Glance

  • 2.1 Market Share (%) Distribution of B -thalassemia in 2017
  • 2.2 Market Share (%) Distribution of B -thalassemia in 2028

3 Disease Background and Overview

  • 3.1 Introduction
  • 3.2 Types
  • 3.3 Molecular Genetics
  • 3.4 Causes and risk factors
  • 3.5 Complications associated with Beta-thalassemia
  • 3.6 Etiology
  • 3.7 Symptoms
  • 3.8 Pathophysiology
  • 3.9 Clinical Presentation of Beta-Thalassemia
  • 3.1 Diagnosis

4 Epidemiology and Patient Population

  • 4.1 Key Findings
  • 4.2 Total Diagnosed Prevalence of B-thal in 10 Emerging Markets

5 Country Wise-Epidemiology of Beta-Thal

  • 5.1 Assumptions and Rationale
  • 5.2 China
    • 5.2.1 Total Prevalent Cases of B-thal in China
    • 5.2.2 Diagnosed Prevalence of B-thal in China
    • 5.2.3 Diagnosed B-thal Patients by Disease Type in China
    • 5.2.4 Complications of B-thalassemia Patients in China
  • 5.3 Taiwan
    • 5.3.1 Total Prevalent Cases of B-thal in Taiwan
    • 5.3.2 Diagnosed Prevalence of B-thal in Taiwan
    • 5.3.3 Diagnosed B-thal Patients by Disease Type in Taiwan
    • 5.3.4 Complications of B-thalassemia Patients in Taiwan
  • 5.4 Saudi Arabia
    • 5.4.1 Total Prevalent Cases of B-thal in Saudi Arabia
    • 5.4.2 Diagnosed Prevalence of B-thal in Saudi Arabia
    • 5.4.3 Diagnosed B-thal Patients by Disease Type in Saudi Arabia
    • 5.4.4 Complications of B-thalassemia Patients in Saudi Arabia
  • 5.5 UAE
    • 5.5.1 Total Prevalent Cases of B-thal in UAE
    • 5.5.2 Diagnosed Prevalence of B-thal in UAE
    • 5.5.3 Diagnosed B-thal Patients by Disease Type in UAE
    • 5.5.4 Complications of B-thalassemia Patients in UAE
  • 5.6 Turkey
    • 5.6.1 Total Prevalent Cases of B-thal in Turkey
    • 5.6.2 Diagnosed Prevalence of B-thal in Turkey
    • 5.6.3 Diagnosed B-thal Patients by Disease Type in Turkey
    • 5.6.4 Complications of B-thalassemia Patients in Turkey
  • 5.7 Russia
    • 5.7.1 Total Prevalent Cases of B-thal in Russia
    • 5.7.2 Diagnosed Prevalence of B-thal in Russia
    • 5.7.3 Diagnosed B-thal Patients by Disease Type in Russia
    • 5.7.4 Complications of B-thalassemia Patients in Russia
  • 5.8 Colombia
    • 5.8.1 Total Prevalent Cases of B-thal in Colombia
    • 5.8.2 Diagnosed Prevalence of B-thal in Colombia
    • 5.8.3 Diagnosed B-thal Patients by Disease Type in Colombia
    • 5.8.4 Complications of B-thalassemia Patients in Colombia
  • 5.9 Brazil
    • 5.9.1 Total Prevalent Cases of B-thal in Brazil
    • 5.9.2 Diagnosed Prevalence of B-thal in Brazil
    • 5.9.3 Diagnosed B-thal Patients by Disease Type in Brazil
    • 5.9.4 Complications of B-thalassemia Patients in Brazil
  • 5.1 Argentina
    • 5.10.1 Total Prevalent Cases of B-thal in Argentina
    • 5.10.2 Diagnosed Prevalence of B-thal in Argentina
    • 5.10.3 Diagnosed B-thal Patients by Disease Type in Argentina
    • 5.10.4 Complications of B-thalassemia Patients in Argentina
  • 5.11 Mexico
    • 5.11.1 Total Prevalent Cases of B-thal in Mexico
    • 5.11.2 Diagnosed Prevalence of B-thal in Mexico
    • 5.11.3 Diagnosed B-thal Patients by Disease Type in Mexico
    • 5.11.4 Complications of B-thalassemia Patients in Mexico

6 Treatment and Management of Beta-thalassemia

  • 6.1 Transfusion therapy
  • 6.2 Iron Chelation Therapy
  • 6.3 Treatment of Iron-overload Complications
  • 6.4 Bone Marrow and Cord Blood Transplantation
  • 6.5 Fetal Hemoglobin Induction
  • 6.6 Gene therapy

7 Unmet Needs

8 Appendix

  • 8.1 Report Methodology

9 DelveInsight Capabilities

10 Disclaimer

11 About DelveInsight

List of Tables

  • Table 1: Difference between Beta-thalassemia major and intermediate based on different parameters
  • Table 2: Diagnosed Prevalence of B-thal in 10 Emerging Markets (2017-2028)
  • Table 3: Total Prevalent Cases B-thal in China (2017-2028)
  • Table 4: Diagnosed Prevalence of B-thal in China (2017-2028)
  • Table 5: Diagnosed B-thal Patients by Disease Type in China (2017-2028)
  • Table 6: Complications of B-thalassemia Patients in China (2017-2028)
  • Table 7: Total Prevalence Cases of B-thal in Taiwan (2017-2028)
  • Table 8: Diagnosed Prevalence of B-thal by Types in Taiwan (2017-2028)
  • Table 9: Diagnosed B-thal Patients by Disease Type in Taiwan (2017-2028)
  • Table 10: Complications of B-thalassemia Patients in Taiwan (2017-2028)
  • Table 11: Total Prevalence Cases of B-thal in Saudi Arabia (2017-2028)
  • Table 12: Diagnosed Prevalence of B-thal in Saudi Arabia (2017-2028)
  • Table 13: Diagnosed B-thal Patients by Disease Type in Saudi Arabia (2017-2028)
  • Table 14: Complications of B-thalassemia Patients in Saudi Arabia (2017-2028)
  • Table 15: Total Prevalence Cases of B-thal in UAE (2017-2028)
  • Table 16: Diagnosed Prevalence of B-thal in UAE (2017-2028)
  • Table 17: Diagnosed B-thal Patients by Disease Type in UAE (2017-2028)
  • Table 18: Complications of B-thalassemia Patients in UAE (2017-2028)
  • Table 19: Total Prevalence Cases of B-thal in Turkey (2017-2028)
  • Table 20: Diagnosed Prevalence of B-thal in Turkey (2017-2028)
  • Table 21: Diagnosed B-thal Patients by Disease Type in Turkey (2017-2028)
  • Table 22: Complications of B-thalassemia Patients in Turkey (2017-2028)
  • Table 23: Total Prevalence Cases of B-thal in Russia (2017-2028)
  • Table 24: Diagnosed Prevalence of B-thal in Russia (2017-2028)
  • Table 25: Diagnosed B-thal Patients by Disease Type in Russia (2017-2028)
  • Table 26: Complications of B-thalassemia Patients in Russia (2017-2028)
  • Table 27: Total Prevalence Cases of B-thal in Colombia (2017-2028)
  • Table 28: Diagnosed Prevalence of B-thal in Colombia (2017-2028)
  • Table 29: Diagnosed B-thal Patients by Disease Type in Colombia (2017-2028)
  • Table 30: Complications of B-thalassemia Patients in Colombia (2017-2028)
  • Table 31: Total Prevalence Cases of B-thal in Brazil (2017-2028)
  • Table 32: Diagnosed Prevalence of B-thal in Brazil (2017-2028)
  • Table 33: Diagnosed B-thal Patients by Disease Type in Brazil (2017-2028)
  • Table 34: Complications of B-thalassemia Patients in Brazil (2017-2028)
  • Table 35: Total Prevalence Cases of B-thal in Argentina (2017-2028)
  • Table 36: Diagnosed Prevalence of B-thal in Argentina (2017-2028)
  • Table 37: Diagnosed B-thal Patients by Disease Type in Argentina (2017-2028)
  • Table 38: Complications of B-thalassemia Patients in Argentina (2017-2028)
  • Table 39: Total Prevalence Cases of B-thal in Mexico (2017-2028)
  • Table 40: Diagnosed Prevalence of B-thal in Mexico (2017-2028)
  • Table 41: Diagnosed B-thal Patients by Disease Type in Mexico (2017-2028)
  • Table 42: Complications of B-thalassemia Patients in Mexico (2017-2028)
  • Table 43: Comparison of three leading iron chelators for treatment of beta-thalassemia
  • Table 44: Frequencies of various complications and treatment of Beta-thalassemia

List of Figures

  • Figure 1: Chromosome 11
  • Figure 2: Red blood cells
  • Figure 3: Classification of Beta-thalassemia by
  • Figure 4: Inheritance pattern of Beta-thalassemia
  • Figure 5: Possible complications associated with Beta-thalassemia
  • Figure 6: Symptoms of Beta-thalassemia
  • Figure 7: Pathophysiology of Beta-thalassemia
  • Figure 8: Clinical and Psychosocial concerns among patient's in different age-groups
  • Figure 9: Diagnostic algorithm of Beta-thalassemia
  • Figure 10: Diagnosed Prevalence of B-thal in 10 Emerging Markets (2017-2028)
  • Figure 11: Total Prevalent Cases of B-thal in China (2017-2028)
  • Figure 12: Diagnosed Prevalence of B-thal in China (2017-2028)
  • Figure 13: Diagnosed B-thal Patients by Disease Type in China (2017-2028)
  • Figure 14: Complications of B-thalassemia Patients in China (2017-2028)
  • Figure 15: Total Prevalence Cases of B-thal in Taiwan (2017-2028)
  • Figure 16: Diagnosed Prevalence of B-thal by Types in Taiwan (2017-2028)
  • Figure 17: Diagnosed B-thal Patients by Disease Type in Taiwan (2017-2028)
  • Figure 18: Complications of B-thalassemia Patients in Taiwan (2017-2028)
  • Figure 19: Total Prevalence Cases of B-thal in Saudi Arabia (2017-2028)
  • Figure 20: Diagnosed Prevalence of B-thal in Saudi Arabia (2017-2028)
  • Figure 21: Diagnosed B-thal Patients by Disease Type in Saudi Arabia (2017-2028)
  • Figure 22: Complications of B-thalassemia Patients in Saudi Arabia (2017-2028)
  • Figure 23: Total Prevalence Cases of B-thal in UAE (2017-2028)
  • Figure 24: Diagnosed Prevalence of B-thal in UAE (2017-2028)
  • Figure 25: Diagnosed B-thal Patients by Disease Type in UAE (2017-2028)
  • Figure 26: Complications of B-thalassemia Patients in UAE (2017-2028)
  • Figure 27: Total Prevalence Cases of B-thal in Turkey (2017-2028)
  • Figure 28: Diagnosed Prevalence of B-thal in Turkey (2017-2028)
  • Figure 29: Diagnosed B-thal Patients by Disease Type in Turkey (2017-2028)
  • Figure 30: Complications of B-thalassemia Patients in Turkey (2017-2028)
  • Figure 31: Total Prevalence Cases of B-thal in Russia (2017-2028)
  • Figure 32: Diagnosed Prevalence of B-thal in Russia (2017-2028)
  • Figure 33: Diagnosed B-thal Patients by Disease Type in Russia (2017-2028)
  • Figure 34: Complications of B-thalassemia Patients in Russia (2017-2028)
  • Figure 35: Total Prevalence Cases of B-thal in Colombia (2017-2028)
  • Figure 36: Diagnosed Prevalence of B-thal in Colombia (2017-2028)
  • Figure 37: Diagnosed B-thal Patients by Disease Type in Colombia (2017-2028)
  • Figure 38: Complications of B-thalassemia Patients in Colombia (2017-2028)
  • Figure 39: Total Prevalence Cases of B-thal in Brazil (2017-2028)
  • Figure 40: Diagnosed Prevalence of B-thal in Brazil (2017-2028)
  • Figure 41: Diagnosed B-thal Patients by Disease Type in Brazil (2017-2028)
  • Figure 42: Complications of B-thalassemia Patients in Brazil (2017-2028)
  • Figure 43: Total Prevalence Cases of B-thal in Argentina (2017-2028)
  • Figure 44: Diagnosed Prevalence of B-thal in Argentina (2017-2028)
  • Figure 45: Diagnosed B-thal Patients by Disease Type in Argentina (2017-2028)
  • Figure 46: Complications of B-thalassemia Patients in Argentina (2017-2028)
  • Figure 47: Total Prevalence Cases of B-thal in Mexico (2017-2028)
  • Figure 48: Diagnosed Prevalence of B-thal in Mexico (2017-2028)
  • Figure 49: Diagnosed B-thal Patients by Disease Type in Mexico (2017-2028)
  • Figure 50: Complications of B-thalassemia Patients in Mexico (2017-2028)
  • Figure 51: Overview of current management of Beta-Thalassemia
  • Figure 52: Beta-thalassemia and its severity based on transfusion dependency
  • Figure 53: Amelioration of ROS by iron chelators and antioxidants
  • Figure 54: Unmet needs